Ocugenix
The startup develops small molecule immunotherapy drugs targeting ocular diseases, specifically designed to combat drug-resistant bacteria while limiting fibrosis and angiogenesis. This approach enables effective treatment of cancer-related eye conditions, enhancing patient outcomes in a challenging therapeutic area.
Traction –/10
Pittsburgh, United States · HQ
- Biotechnology
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops small molecule immunotherapy drugs targeting ocular diseases, specifically designed to combat drug-resistant bacteria while limiting fibrosis and angiogenesis. This approach enables effective treatment of cancer-related eye conditions, enhancing patient outcomes in a challenging therapeutic area.